These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 20112342)

  • 1. ADAM28 is a serological and histochemical marker for non-small-cell lung cancers.
    Kuroda H; Mochizuki S; Shimoda M; Chijiiwa M; Kamiya K; Izumi Y; Watanabe M; Horinouchi H; Kawamura M; Kobayashi K; Okada Y
    Int J Cancer; 2010 Oct; 127(8):1844-56. PubMed ID: 20112342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ADAM8 as a novel serological and histochemical marker for lung cancer.
    Ishikawa N; Daigo Y; Yasui W; Inai K; Nishimura H; Tsuchiya E; Kohno N; Nakamura Y
    Clin Cancer Res; 2004 Dec; 10(24):8363-70. PubMed ID: 15623614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective study of urinary and serum cross-linked N-telopeptide of type I collagen (NTx) for diagnosis of bone metastasis in patients with lung cancer.
    Tamiya M; Tokunaga S; Okada H; Suzuki H; Kobayashi M; Sasada S; Okamoto N; Morishita N; Matsuura Y; Miyamoto N; Hattori M; Taira K; Daga H; Takeda K; Hirashima T
    Clin Lung Cancer; 2013 Jul; 14(4):364-9. PubMed ID: 23276824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline and decline of serum ADAM28 during chemotherapy of advanced non-small cell lung cancer: a probable predictive and prognostic factor.
    Lv YL; Yuan DM; Wang QB; Zhan P; Luo L; Lv TF; Liu HB; Li YF; Wen J; Song Y
    Med Oncol; 2012 Dec; 29(4):2633-9. PubMed ID: 22354764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer.
    Foss KM; Sima C; Ugolini D; Neri M; Allen KE; Weiss GJ
    J Thorac Oncol; 2011 Mar; 6(3):482-8. PubMed ID: 21258252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer.
    Sirera R; Bremnes RM; Cabrera A; Jantus-Lewintre E; Sanmartín E; Blasco A; Del Pozo N; Rosell R; Guijarro R; Galbis J; Sánchez JJ; Camps C
    J Thorac Oncol; 2011 Feb; 6(2):286-90. PubMed ID: 21252717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma.
    Planque C; Li L; Zheng Y; Soosaipillai A; Reckamp K; Chia D; Diamandis EP; Goodglick L
    Clin Cancer Res; 2008 Mar; 14(5):1355-62. PubMed ID: 18316555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer.
    Chakra M; Pujol JL; Lamy PJ; Bozonnat MC; Quantin X; Jacot W; Daurès JP
    J Thorac Oncol; 2008 Oct; 3(10):1119-26. PubMed ID: 18827607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ADAM28 is overexpressed in human non-small cell lung carcinomas and correlates with cell proliferation and lymph node metastasis.
    Ohtsuka T; Shiomi T; Shimoda M; Kodama T; Amour A; Murphy G; Ohuchi E; Kobayashi K; Okada Y
    Int J Cancer; 2006 Jan; 118(2):263-73. PubMed ID: 16052521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer.
    Vinayanuwattikun C; Sriuranpong V; Tanasanvimon S; Chantranuwat P; Mutirangura A
    J Thorac Oncol; 2011 Nov; 6(11):1818-25. PubMed ID: 21964525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
    Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
    J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical value of p53, c-erbB-2, CEA and CA125 regarding relapse, metastasis and death in resectable non-small cell lung cancer.
    Pollán M; Varela G; Torres A; de la Torre M; Ludeña MD; Ortega MD; Pac J; Freixenet J; Gómez G; Sebastián F; Díez M; Arrabal R; Canalís E; García-Tirado J; Arnedillo A; Rivas JJ; Minguella J; Gómez A; García M; Aragonés N; Pérez-Gómez B; López-Abente G; González-Sarmiento R; Rojas JM
    Int J Cancer; 2003 Dec; 107(5):781-90. PubMed ID: 14566828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum Human Epididymis Secretory Protein 4 (HE4) is a Potential Prognostic Biomarker in Non-Small Cell Lung Cancer.
    Mo D; He F
    Clin Lab; 2018 Sep; 64(9):1421-1428. PubMed ID: 30274019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical usefulness of serum cytokeratin 19 fragment as a tumor marker for lung cancer.
    Maeda Y; Segawa Y; Takigawa N; Takata I; Fujimoto N
    Intern Med; 1996 Oct; 35(10):764-71. PubMed ID: 8933183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum anti-p53 autoantibodies in primary resected non-small-cell lung carcinoma.
    Iizasa T; Fujisawa T; Saitoh Y; Hiroshima K; Ohwada H
    Cancer Immunol Immunother; 1998 Aug; 46(6):345-9. PubMed ID: 9756419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma.
    Okada M; Nishio W; Sakamoto T; Uchino K; Yuki T; Nakagawa A; Tsubota N
    Ann Thorac Surg; 2004 Sep; 78(3):1004-9; discussion 1009-10. PubMed ID: 15337038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the relationship between serum carcinoembryonic antigen level and treatment outcome in surgically resected clinical-stage I patients with non-small-cell lung cancer.
    Hotta K; Segawa Y; Takigawa N; Kishino D; Saeki H; Nakata M; Mandai K; Eguchi K
    Anticancer Res; 2000; 20(3B):2177-80. PubMed ID: 10928173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.
    Okuma Y; Wakui H; Utsumi H; Sagawa Y; Hosomi Y; Kuwano K; Homma S
    Clin Lung Cancer; 2018 Sep; 19(5):410-417.e1. PubMed ID: 29859759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
    Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
    J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.